BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22131152)

  • 21. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
    Thompson RC; Vardinogiannis I; Gilmore TD
    PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
    Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
    BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcellular localization of PUMA regulates its pro-apoptotic activity in Burkitt's lymphoma B cells.
    Ambroise G; Portier A; Roders N; Arnoult D; Vazquez A
    Oncotarget; 2015 Nov; 6(35):38181-94. PubMed ID: 26431330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.
    Anderton E; Yee J; Smith P; Crook T; White RE; Allday MJ
    Oncogene; 2008 Jan; 27(4):421-33. PubMed ID: 17653091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
    Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway.
    Hu T; Gao Y
    Biomed Pharmacother; 2018 Oct; 106():1557-1562. PubMed ID: 30119230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
    Gómez-Benito M; Marzo I; Anel A; Naval J
    Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis.
    Han J; Goldstein LA; Gastman BR; Rabinowich H
    J Biol Chem; 2006 Apr; 281(15):10153-63. PubMed ID: 16478725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
    Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
    Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
    Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
    Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
    Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
    Yoshida A; Takemura H; Inoue H; Miyashita T; Ueda T
    Cancer Res; 2006 Jun; 66(11):5772-80. PubMed ID: 16740716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
    Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
    Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance.
    Zantl N; Weirich G; Zall H; Seiffert BM; Fischer SF; Kirschnek S; Hartmann C; Fritsch RM; Gillissen B; Daniel PT; Häcker G
    Oncogene; 2007 Oct; 26(49):7038-48. PubMed ID: 17486061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
    Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
    Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.